Ieq Capital LLC Invests $20.32 Million in Medpace Holdings, Inc. $MEDP

Ieq Capital LLC bought a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the 2nd quarter, according to its most recent filing with the SEC. The firm bought 38,375 shares of the company’s stock, valued at approximately $20,323,000. Ieq Capital LLC owned 0.14% of Medpace as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Heron Bay Capital Management acquired a new position in shares of Medpace during the second quarter worth $16,038,000. Callan Family Office LLC purchased a new stake in Medpace during the 2nd quarter worth $252,000. Keebeck Wealth Management purchased a new stake in Medpace during the 2nd quarter worth $635,000. Allworth Financial LP acquired a new position in Medpace in the 2nd quarter worth $2,062,000. Finally, B. Metzler seel. Sohn & Co. AG acquired a new position in Medpace in the 2nd quarter worth $4,737,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Insider Activity at Medpace

In related news, VP Susan E. Burwig sold 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $600.00, for a total value of $4,500,000.00. Following the sale, the vice president owned 62,984 shares of the company’s stock, valued at approximately $37,790,400. This trade represents a 10.64% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Fred B. Davenport, Jr. sold 7,283 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $606.15, for a total value of $4,414,590.45. Following the transaction, the director owned 3,798 shares of the company’s stock, valued at $2,302,157.70. This represents a 65.73% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 122,261 shares of company stock valued at $71,729,129. 20.50% of the stock is owned by insiders.

Analyst Ratings Changes

A number of analysts have recently issued reports on MEDP shares. Robert W. Baird lifted their target price on Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a research report on Friday, July 24th. Wall Street Zen lowered Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $535.00 price objective on shares of Medpace in a report on Thursday, July 23rd. Barclays set a $600.00 target price on Medpace in a research report on Thursday, July 23rd. Finally, Truist Financial raised their price target on shares of Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Three equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $584.18.

Medpace Trading Up 1.3%

Shares of MEDP opened at $620.75 on Friday. Medpace Holdings, Inc. has a 52 week low of $373.00 and a 52 week high of $677.90. The firm has a market cap of $17.33 billion, a price-to-earnings ratio of 36.39, a PEG ratio of 2.73 and a beta of 1.15. The stock has a 50 day moving average of $550.16 and a 200-day moving average of $492.71.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. The business had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, sell-side analysts predict that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.